학술논문
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Document Type
Article
Author
Lheureux, S.; Bruce, J.P.; Garg, S.; Cabanero, M.; Dhani, N.C.; Stockley, T.; Karakasis, K.; Tan, Q.; Bowering, V.; Udagani, S.; Wang, L.; Chen, E.; Pugh, T.J.; Oza, A.M.; Cristea, M.C.; Mantia-Smaldone, G.; Olawaiye, A.B.; Ellard, S.L.; Weberpals, J.I.; Wahner Hendrickson, A.E.; Fleming, G.F.; Welch, S.; Rath, P.; Jones, G.N.; Jenkins, S.; Rodriguez-Canales, J.; Tracy, M.; Kunos, C.A.
Source
In: The Lancet . (The Lancet, 23 January 2021, 397(10271):281-292)
Subject
Language
English
ISSN
1474547X
01406736
01406736